Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | UBE2N | P61088 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721221 | 1.00 | TACR2 (0.54) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL5213944 | 1.00 | TACR2 (0.54) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4576841 | 0.94 | FDPS (0.57) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL5218024 | 0.94 | AKR1C3 (0.56) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL30628477 | 0.93 | TACR2 (0.53) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL21427196 | 0.93 | TACR2 (0.53) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL5219137 | 0.92 | TACR2 (0.67) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL21427052 | 0.92 | TACR2 (0.52) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL30880067 | 0.92 | TACR2 (0.52) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 | |
| SCHEMBL584489 | 0.91 | TACR2 (0.62) | TACR2MAOAMAOBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828163-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | AUTOTAC INC (KR) | 2026-05-20 | — | — | EP | disclosed |
| EP-3828164-B1 | NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME | AUTOTAC INC (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2025-09-30 | — | — | US | disclosed |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3828162-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES COMPRISING THE SAME | AUTOTAC INC (KR) | 2025-07-09 | — | — | EP | disclosed |
| US-12129218-B2 | AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same | AUTOTAC INC. (KR) | 2024-10-29 | — | — | US | disclosed |
| US-11981618-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2024-05-14 | — | — | US | disclosed |
| CN-112424160-B | Novel P62 ligand compound and composition for preventing, improving or treating protein conformational diseases comprising the same | 奧土择破利悟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-112672993-B | Novel AUTOTAC chimeric compounds and compositions comprising same for preventing, ameliorating or treating diseases by targeted protein degradation | 奧土择破利悟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-112424159-B | Novel P62 ligand compound and composition for preventing, improving or treating protein conformational diseases comprising the same | 普罗泰克株式会社 | 2023-10-31 | — | — | CN | disclosed |
| WO-2020256444-A1 | P62 LIGAND COMPOUND AND ER-PHAGY-PROMOTING USE THEREOF | 서울대학교산학협력단 | 2020-12-24 | — | — | WO | disclosed |
| WO-2020022783-A9 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS | 주식회사 프로텍바이오 | 2020-03-19 | — | — | WO | disclosed |
| WO-2020022785-A1 | NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME | 주식회사 프로텍바이오 | 2020-01-30 | — | — | WO | disclosed |
| WO-2020022783-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS | 주식회사 프로텍바이오 | 2020-01-30 | — | — | WO | disclosed |
| WO-2020022783-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS | 주식회사 프로텍바이오 | 2020-01-30 | — | — | WO | disclosed |
| WO-2020022784-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | 주식회사 프로텍바이오 | 2020-01-30 | — | — | WO | disclosed |
| WO-2020022784-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | 주식회사 프로텍바이오 | 2020-01-30 | — | — | WO | disclosed |
| WO-2019190172-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING SAME | 주식회사 프로텍바이오 | 2019-10-03 | — | — | WO | disclosed |
| US-5495046-A | PSYCHOLOGICAL DISORDERS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1996-02-27 | — | — | US | disclosed |
| EP-0641766-A1 | ALKOXYPHENYLALKYLAMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | TACR2 4471/4885MAOA 4624/4885MAOB 4703/4885 |
| US-12129218-B2 | AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same | ATG7, SQSTM1, CTSA | TACR2 4253/4885MAOA 3151/4885MAOB 3877/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | TACR2 3442/4885MAOA 3080/4885MAOB 3711/4885 |
| US-11981618-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | TACR2 4532/4885MAOA 4814/4885MAOB 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.